MindWalk Holdings Corp. Reports Mixed Q3 Results, Revenue Growth Offsets EPS Miss
MINDWALK HOLDINGS CORP (NASDAQ:HYFT), a company specializing in AI-driven biologics discovery, has released its financial results for the third quarter of fiscal year 2026, ended January 31, 2026. The report presents a dual narrative of robust revenue growth paired with a continued net loss, leading to a mixed market reception in early trading.
Financial Performance vs. Estimates
The company's top-line performance showed significant strength, though it fell short of analyst expectations. Meanwhile, the bottom-line loss was wider than anticipated.
- Revenue: Q3 revenue reached $4.2 million (CAD), marking a substantial 52% increase from the $2.7 million reported in the same quarter last year. However, this result came in below the analyst consensus estimate of $4.7 million.
- Earnings Per Share (EPS): The net loss from continuing operations was $3.9 million, resulting in an EPS loss of $(0.08). This was deeper than the estimated EPS loss of $(0.06) projected by analysts.
The company's nine-month revenue stands at $11.4 million, a 45% increase over the prior year period. Gross margin for the quarter was 59%, a decrease from 65% in Q3 FY2025, which the company did not explicitly address in its highlights. Cash and cash equivalents were reported at $14.2 million as of January 31, 2026.
Market Reaction and Strategic Shifts
Following the earnings release, the stock has shown modest positive movement in pre-market trading, suggesting investors may be focusing on the strong year-over-year growth trajectory and operational milestones rather than the quarterly miss against estimates. This reaction underscores a longer-term view of the company's strategic repositioning.
A key theme from the quarter is MindWalk's deliberate pivot toward the North American market. The divestiture of its European operations and the establishment of biologics services in the Boston and Cambridge area appear to be bearing fruit, with U.S. revenue doubling year-over-year to $2.6 million. Furthermore, the company secured its first one-year, recurring platform contract for its LensAI technology with its largest enterprise AI client, signaling a strategic shift from project-based to more predictable contracted revenue.
Pipeline and Operational Highlights
Beyond the financials, MindWalk provided substantial updates on its development pipeline, which forms the core of its long-term value proposition:
- Platform & Commercial: The first enterprise LensAI platform contract was signed, with services now being delivered directly to clients. The strategic focus on North America was emphasized as a driver behind the U.S. revenue surge.
- B cell Llama™ Platform: The company launched a new nanobody discovery platform built on single B cell isolation from immunized llamas, targeting the bispecific and multispecific antibody market.
- Dengue Vaccine Program: In vivo immunization studies are complete, with binding confirmation results anticipated imminently. The program, which aims to address all four dengue serotypes, will then advance to neutralization testing.
- GLP-1 Program: In vitro receptor activation has been confirmed by a third party, showing activity relative to semaglutide. The program is advancing with guidance from a large pharmaceutical collaborator.
- Influenza Program: The LensAI platform has screened over two thousand influenza sequences, identifying a single conserved feature. The program is advancing into manufacturing for neutralization studies.
- Asset Financing: The company has engaged advisors to design asset-level financing vehicles for its proprietary portfolio, aiming to attract targeted investment while preserving equity.
Outlook and Analyst Projections
The press release did not provide specific quantitative financial guidance for the coming quarters or full year. This leaves analyst estimates as the primary benchmark for future performance. Currently, analysts are forecasting a sequential improvement for Q4 FY2026, with an estimated revenue of $5.2 million and a reduced EPS loss of $(0.05). For the full fiscal year 2026, the sales estimate stands at $17.3 million.
Conclusion
MindWalk's Q3 report illustrates a company in transition, successfully accelerating revenue growth and achieving key commercial and platform milestones while still navigating the costly path of therapeutic development. The miss on both revenue and EPS estimates highlights the challenges of forecasting for a clinical-stage biotech. However, the market's initial tempered positive reaction suggests investors are weighing the strategic progress—particularly the North American focus and the shift to recurring revenue—against the quarterly financial shortfall. The company’s ability to advance its pipeline programs and secure non-dilutive asset financing will be critical watchpoints moving forward.
For a detailed look at historical earnings and future analyst projections, you can review the earnings history and estimates page for HYFT.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.